Wanggang Zhang Selected Research

Immunotherapy

1/2021	Identification of HLA-A*0201-restricted CTL Epitopes for MLAA-34-specific Immunotherapy for Acute Monocytic Leukemia.
10/2019	Management of cytokine release syndrome related to CAR-T cell therapy.
1/2019	Regulation of expression of MLAA-34 gene through transcriptional factors E2F1 and MZF-1.
11/2017	Current treatment options of T cell-associated immunotherapy in multiple myeloma.
4/2017	Immunological effects of vaccines combined with granulocyte colony-stimulating factor on a murine WEHI-3 leukemia model.
2/2017	Bioinformatic prediction and functional characterization of human KIAA0100 gene.
1/2017	A novel multi-epitope vaccine from MMSA-1 and DKK1 for multiple myeloma immunotherapy.
12/2014	Prediction and identification of HLA-A*0201-restricted epitopes from leukemia-associated protein MLAA-22 which elicit cytotoxic T lymphocytes.
9/2012	Anti-tumor immune responses in immune-reconstituted mice injected with a tumor vaccine.
2/2011	Screening of novel immunostimulatory CpG ODNs and their anti-leukemic effects as immunoadjuvants of tumor vaccines in murine acute lymphoblastic leukemia.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Wanggang Zhang Research Topics

Disease

23	Leukemia 01/2021 - 01/2004
14	Neoplasms (Cancer) 01/2021 - 03/2010
14	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 06/2020 - 05/2005
12	Multiple Myeloma 02/2024 - 06/2012
5	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2020 - 02/2011
4	Acute Monocytic Leukemia (Acute Monoblastic Leukemia) 01/2021 - 05/2005
4	Residual Neoplasm 01/2020 - 02/2011
3	Carcinogenesis 01/2020 - 02/2017
2	Hematologic Neoplasms (Hematological Malignancy) 10/2023 - 10/2019
2	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 02/2020 - 09/2018
2	Aplastic Anemia (Anemia, Hypoplastic) 12/2017 - 03/2016
1	Disseminated Intravascular Coagulation 10/2023
1	Multi-centric Castleman's Disease 02/2023
1	Memory Disorders (Memory Loss) 01/2022
1	Asthma (Bronchial Asthma) 01/2022
1	Airway Remodeling 01/2022
1	Cognitive Dysfunction 01/2022
1	Hypophosphatemia 01/2021
1	Philadelphia Chromosome 01/2021
1	Pain (Aches) 01/2021
1	Blast Crisis (Blast Phase) 01/2021
1	Neutropenia 01/2021
1	Diarrhea 01/2021
1	Edema (Dropsy) 01/2021
1	Exanthema (Rash) 01/2021
1	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2021
1	Anemia 01/2021
1	Iron Overload 02/2020
1	Immune System Diseases (Immune Disorders) 01/2020
1	Autoimmune Diseases (Autoimmune Disease) 01/2020
1	Hyperthermia 10/2019
1	Lymphoma (Lymphomas) 10/2019
1	Respiratory Insufficiency (Respiratory Failure) 10/2019
1	Shock 10/2019
1	Disease Progression 01/2019
1	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2019
1	Atherosclerosis 12/2018
1	Cardiovascular Diseases (Cardiovascular Disease) 12/2018
1	Hemophagocytic Lymphohistiocytosis (Hemophagocytic Syndrome) 02/2018

Drug/Important Bio-Agent (IBA)

12	AntigensIBA 01/2021 - 05/2005
7	Proteins (Proteins, Gene)FDA Link 01/2022 - 05/2008
5	MicroRNAs (MicroRNA)IBA 01/2022 - 11/2016
4	Peptides (Polypeptides)IBA 01/2021 - 01/2013
4	EpitopesIBA 01/2021 - 05/2005
4	Biomarkers (Surrogate Marker)IBA 01/2020 - 06/2012
3	Chimeric Antigen ReceptorsIBA 02/2024 - 10/2019
3	HLA-A*02:01 antigenIBA 01/2021 - 12/2014
3	Long Noncoding RNAIBA 06/2020 - 10/2017
3	VaccinesIBA 01/2019 - 09/2012
3	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 11/2018 - 04/2017
3	Complementary DNA (cDNA)IBA 06/2017 - 01/2004
3	Messenger RNA (mRNA)IBA 11/2016 - 05/2008
2	B-Cell Maturation AntigenIBA 02/2024 - 10/2023
2	Immunologic Adjuvants (Immunologic Adjuvant)IBA 01/2021 - 02/2011
2	CytokinesIBA 01/2021 - 11/2016
2	Therapeutic UsesIBA 01/2021 - 12/2010
2	IronIBA 02/2020 - 05/2017
2	DNA (Deoxyribonucleic Acid)IBA 01/2019 - 05/2005
2	thymoglobulin FDA Link 12/2017 - 03/2016
2	CateninsIBA 01/2017 - 01/2015
2	Cancer VaccinesIBA 09/2012 - 02/2011
1	bis(3- bis(4- chlorophenyl)methyl- 4- dimethylaminophenyl)amineIBA 02/2024
1	Dacarbazine (DIC)FDA LinkGeneric 10/2023
1	Mycophenolic Acid (Cellcept)FDA LinkGeneric 02/2023
1	Methylprednisolone FDA LinkGeneric 02/2023
1	Immunosuppressive Agents (Immunosuppressants)IBA 02/2023
1	pyrazolanthroneIBA 01/2022
1	isorhapontigeninIBA 01/2022
1	CCCTC-Binding FactorIBA 01/2022
1	Acetylcholine (Acetylcholine Chloride)FDA Link 01/2022
1	AcetylcholinesteraseIBA 01/2022
1	JNK Mitogen-Activated Protein KinasesIBA 01/2022
1	flumatinibIBA 01/2021
1	Protein Subunit VaccinesIBA 01/2021
1	Imatinib Mesylate (Gleevec)FDA Link 01/2021
1	Alanine Transaminase (SGPT)IBA 01/2021
1	Caspase 3 (Caspase-3)IBA 01/2020
1	Factor X (Stuart Factor)IBA 01/2020
1	Thalidomide (Thalomid)FDA Link 12/2019
1	Platelet Factor 4IBA 12/2019
1	tocilizumab (atlizumab)FDA Link 10/2019
1	Interleukin-17 (Interleukin 17)IBA 06/2019
1	Nicotinamide PhosphoribosyltransferaseIBA 06/2019
1	RNA (Ribonucleic Acid)IBA 01/2019
1	Ribonuclease P (RNase P)IBA 01/2019
1	oxidized low density lipoproteinIBA 12/2018
1	Endothelins (Endothelin)IBA 12/2018
1	AclarubicinIBA 09/2018
1	Cytarabine (Cytosar-U)FDA LinkGeneric 09/2018
1	Cell Surface ReceptorsIBA 01/2018
1	fluorine monoxideIBA 01/2018
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2018

Therapy/Procedure

11	Immunotherapy 01/2021 - 05/2005
8	Therapeutics 02/2024 - 03/2010
5	Drug Therapy (Chemotherapy) 11/2018 - 01/2013
3	Induction Chemotherapy 01/2019 - 01/2016
2	Salvage Therapy 02/2024 - 11/2018
1	Aftercare (After-Treatment) 01/2021
1	Chelation Therapy (Therapy, Chelation) 02/2020
1	Blood Transfusion (Blood Transfusions) 02/2020